US welcomes Idacio and Hulio to Adalimumab biosimilars market
The US biosimilars market gains 2 more adalimumab products: Idacio by Fresenius Kabi (adalimumab-aacf) and Hulio by Biocon Biologic (adalimumab-fkjp). Both Idacio and Hulio refer to Humira (adalimumab), one of the most profitable drugs in the world. Throughout July 2023, 8 biosimilars of adalimumab are planned to be launched in the United States. The launches … Read more